[Cervix priming in induced abortion in the 1st trimester using intracervical administration of sulprostone gel].
In a prospective, randomised study 40 primigravidae were treated intracervically with 0.05 mg or 0.1 mg Sulprostone-Tylose gel in order to soften the cervix prior to first trimester termination of pregnancy. Curettage was performed on the average 7.5 hours after prostaglandin administration. For objective demonstration of the priming effect, the force required for dilatation of the cervical canal was measured in Newtons by a special tonometer before prostaglandin application and before operation. The maximal dilatability with a force of 10 N, the increase in dilatability after local PG application, and the patency of the cervix were measured. The occurrence of PG-induced lower abdominal pain associated with contractions was analysed with regard to the number of episodes at pain, their timing and the required amount of analgesics. A modified visual analogue scale was used to evaluate the subjective pain experience. The abortive effect of 0.1 mg Sulprostone was found to be more efficient than the 0.05 mg dose. There was no statistical significant difference between the two doses, however, for the priming effect detectable with the tonometer. The subjective experience of pain, use of analgesics and the frequency of gastrointestinal side effects were significantly higher with 0.1 mg than with 0.05 mg Sulprostone. The visual analogue scale allows the patient to quantify, at least to some extent, her experience of pain, and enables a differentiated analgetic therapy. Because of its effectiveness and low rate of side effects, the intracervical application of 0.05 mg Sulprostone gel promises to be an advantageous alternative to other methods of cervical priming.
D000019:Abortifacient Agents / Q000009:adverse effects; D000020:Abortifacient Agents, Nonsteroidal / Q000009:adverse effects; D000028:Abortion, Induced / Q000379:methods*; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D004107:Dilatation and Curettage / Q000295:instrumentation; D015232:Dinoprostone / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005782:Gels; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011459:Prostaglandins E, Synthetic / Q000009:adverse effects
D000019:Abortifacient Agents; D000020:Abortifacient Agents, Nonsteroidal; D005782:Gels; D011459:Prostaglandins E, Synthetic; C016767:sulprostone; D015232:Dinoprostone
Zervixpriming beim Schwangerschaftsabbruch im I. Trimenon mittels intrazervikaler Applikation von Sulproston-Gel.